Jackson Wealth Management LLC Sells 41,939 Shares of Boston Scientific Corporation $BSX

Jackson Wealth Management LLC trimmed its position in Boston Scientific Corporation (NYSE:BSX) by 88.8% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 5,306 shares of the medical equipment provider’s stock after selling 41,939 shares during the quarter. Jackson Wealth Management LLC’s holdings in Boston Scientific were worth $226,000 at the end of the most recent quarter.

Several other large investors have also added to or reduced their stakes in BSX. FWL Investment Management LLC purchased a new stake in shares of Boston Scientific in the second quarter worth $26,000. Swiss RE Ltd. bought a new position in Boston Scientific in the 4th quarter worth $26,000. Garton & Associates Financial Advisors LLC bought a new position in Boston Scientific in the 4th quarter worth $26,000. Sfam LLC purchased a new stake in Boston Scientific in the 4th quarter worth $29,000. Finally, Cresta Advisors Ltd. purchased a new stake in Boston Scientific in the 4th quarter worth $33,000. Hedge funds and other institutional investors own 89.07% of the company’s stock.

Analyst Ratings Changes

BSX has been the subject of a number of recent analyst reports. Zacks Research lowered Boston Scientific from a “hold” rating to a “strong sell” rating in a research note on Friday, June 5th. Needham & Company LLC lowered their price target on Boston Scientific from $77.00 to $57.00 and set a “buy” rating on the stock in a report on Wednesday, July 8th. Oppenheimer cut their price objective on shares of Boston Scientific from $90.00 to $85.00 and set an “outperform” rating for the company in a report on Monday, July 27th. Weiss Ratings cut shares of Boston Scientific from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Tuesday, July 7th. Finally, Bank of America dropped their target price on shares of Boston Scientific from $105.00 to $68.00 and set a “buy” rating for the company in a research report on Monday, May 18th. Twenty-four investment analysts have rated the stock with a Buy rating, five have assigned a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $71.62.

Boston Scientific Stock Performance

NYSE BSX opened at $48.35 on Tuesday. The stock has a market capitalization of $70.07 billion, a PE ratio of 19.57, a P/E/G ratio of 1.02 and a beta of 0.56. The business has a 50 day simple moving average of $46.65 and a two-hundred day simple moving average of $56.35. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.24 and a quick ratio of 0.74. Boston Scientific Corporation has a 1-year low of $42.20 and a 1-year high of $109.50.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings data on Wednesday, July 29th. The medical equipment provider reported $0.86 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.83 by $0.03. Boston Scientific had a return on equity of 19.28% and a net margin of 17.50%.The business had revenue of $5.44 billion for the quarter, compared to analysts’ expectations of $5.38 billion. During the same period in the prior year, the firm earned $0.75 EPS. The company’s revenue for the quarter was up 7.5% on a year-over-year basis. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. On average, research analysts predict that Boston Scientific Corporation will post 3.3 EPS for the current fiscal year.

Boston Scientific declared that its Board of Directors has approved a share buyback program on Monday, May 18th that authorizes the company to repurchase $5.00 billion in shares. This repurchase authorization authorizes the medical equipment provider to reacquire up to 6.4% of its stock through open market purchases. Stock repurchase programs are generally an indication that the company’s board believes its shares are undervalued.

Insider Buying and Selling at Boston Scientific

In other Boston Scientific news, CEO Michael F. Mahoney acquired 186,240 shares of the company’s stock in a transaction on Monday, August 3rd. The stock was acquired at an average cost of $48.33 per share, with a total value of $9,000,979.20. Following the purchase, the chief executive officer directly owned 1,590,024 shares of the company’s stock, valued at approximately $76,845,859.92. This represents a 13.27% increase in their position. The purchase was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Edward J. Ludwig bought 5,000 shares of the firm’s stock in a transaction dated Friday, July 31st. The shares were acquired at an average price of $45.48 per share, for a total transaction of $227,400.00. Following the completion of the transaction, the director directly owned 30,359 shares in the company, valued at approximately $1,380,727.32. This represents a 19.72% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders acquired 194,522 shares of company stock worth $9,385,210 over the last 90 days. 0.34% of the stock is owned by insiders.

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.